Glimepiride Tablets is a sulfonylurea hypoglycemic drug that can be used in combination with insulin. In 2001, Glimepiride tablets (Dibei), as the first hypoglycemic product of Beilu Pharma, was first listed in China and belongs to the second class of national new drugs.
Specifications: glimepiride 1 mg×30 tablets；glimepiride 2 mg×15 tablets；glimepiride 2mg×30 tablets
Characteristics: White tablet
As one of the oral antidiabetic drugs produced by Beilu Pharma, our glimepiride tablets are only suitable for type 2 diabetes that cannot fully control blood sugar through diet control, exercise therapy and weight loss.
Glimepiride tablets are not suitable for type 1 diabetes (for example, the treatment of diabetic patients with a history of ketoacidosis), diabetic ketoacidosis or Treatment of pre-diabetic coma or coma.
Usage and Dosage: Please refer to the package insert
Adverse reactions, Contraindications, Precautions: Please refer to the package insert.
Storage: Shade, seal, and keep in a dry place.
Packaging: Aluminum plastic packaging, 15 pills/plate, 1 plate/box; 15 pills/plate, 2 plates/box.
Shelf life: 24 months
Double effect directly hit the hypoglycemic core
Double effect: Glimepiride tablets can promote insulin secretion and improve insulin resistance. At the same time, it can improve the two major pathophysiological abnormalities of insulin secretion and insulin resistance in patients with type 2 diabetes.
Efficiently reduce postprandial blood glucose, fasting blood glucose and glycosylated haemoglobin
Glimepiride tablets monotherapy can comprehensively reduce FPG PPG and HbA1c in newly diagnosed T2DM patients
Combination therapy, such as combined metformin, acarbose, etc., has a more significant overall hypoglycemic effect
Less hypoglycemia, less weight impact, high safety
Short-term treatment, the risk of glimepiride hypoglycemia is only 1/3 of that of Glibenclamide
Long-term treatment, the risk of glimepiride hypoglycemia is only 1/7of that of Glibenclamide
Glimepiride has a small impact on the weight of T2DM patients
Once a day to improve patient compliance
If the patient's compliance is poor, Glimepiride tablets should be selected, once a day.